Neonc Technologies Holdings, Inc.
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.38 | $0 | -$7M |
| 2025 Q4 | -0.81 | $0 | -$4M |
| 2025 Q3 | -0.45 | $0 | -$6M |
| 2025 Q2 | -0.30 | $0 | -$5M |
| 2025 Q1 | -2.10 | $39,990 | -$6M |